Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776903 · ClinicalTrials.gov registry record
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
A clinical trial, sponsored by InBios International.
- Completed
- Registry status
- 600
- Enrollment target
NCT03776903: Completed study, sponsored by InBios International.
NCT03776903 is a clinical trial that has completed, run by InBios International. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03776903 has completed, sponsored by InBios International.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.
Primary Outcome
The positive percent agreement (PPA) and negative percent agreement (NPA) of the ZIKV Detect™ 2.0 IgM Capture ELISA versus the reference test.
Interventions
- OTHER ZIKV Detect™ 2.0 IgM Capture ELISA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2018-09-30 |
What the finished NCT03776903 record still lists
NCT03776903 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ZIKV Detect™ 2.0 IgM Capture ELISA is the first listed.
NCT03776903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03776903 about?
NCT03776903 is a clinical study titled "Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA". The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.
What is the current status of trial NCT03776903?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2018-04-01. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT03776903?
The interventions under investigation include: ZIKV Detect™ 2.0 IgM Capture ELISA (OTHER).
Who is sponsoring clinical trial NCT03776903?
This trial is sponsored by InBios International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI